Search Results

You are looking at 41 - 45 of 45 items for :

  • "hepatitis C virus" x
  • Refine by Access: All x
Clear All
Full access

Al B. Benson III, Michael I. D’Angelica, Thomas A. Abrams, Chandrakanth Are, P. Mark Bloomston, Daniel T. Chang, Bryan M. Clary, Anne M. Covey, William D. Ensminger, Renuka Iyer, R. Kate Kelley, David Linehan, Mokenge P. Malafa, Steven G. Meranze, James O. Park, Timothy Pawlik, James A. Posey, Courtney Scaife, Tracey Schefter, Elin R. Sigurdson, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Yun Yen, Andrew X. Zhu, Karin G. Hoffmann, Nicole R. McMillian, and Hema Sundar

cholangiocarcinoma. 44 Other potential but less-established risk factors include inflammatory bowel disease, hepatitis C virus, hepatitis B virus, cirrhosis, diabetes, obesity, alcohol, and tobacco. Recently, several case-controlled studies from Asian and Western

Full access

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC, and Deborah A. Freedman-Cass

dysregulation and coinfection with viruses such as human papillomavirus, human herpesvirus 8 (HHV-8), hepatitis B virus, hepatitis C virus, and Epstein-Barr virus. 12 – 16 In addition, the prevalence of other cancer risk factors in the HIV-positive population

Full access

patients were treated: median age, 70 years (range, 56–82); male, 56%; hepatitis B virus, 33%; hepatitis C virus, 0%; Child Pugh A, 100%; prior sorafenib, 100%; 6 patients in the dose-finding cohort, 3 in the expansion cohort; all patients received ENZA

Full access

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead

. 132 , 181 , 187 Evaluation of HBV and hepatitis C virus infection should be routine in both HSCT recipients and donors. 187 , 188 Vaccination against HBV should be strongly considered in HBV-naïve patients (ie, serology negative for HBsAg, HBsAb, and

Full access

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, Mitesh Borad, Daniel Brown, Adam Burgoyne, Prabhleen Chahal, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, Lipika Goyal, William G. Hawkins, Renuka Iyer, Rojymon Jacob, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Vaibhav Sahai, Tracey Schefter, Gagandeep Singh, Stacey Stein, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole R. McMillian, Cindy Hochstetler, and Susan D. Darlow

cirrhosis and chronic liver disease, regardless of etiology. 6 , 7 Specific risk factors include viral infections caused by hepatitis B virus (HBV) and/or hepatitis C virus (HCV), chronic alcohol consumption, particular comorbidities or other conditions